Axogen is committed to building and maintaining a strong and gratifying company culture that fosters professional growth. Our hands-on and personal approach makes transitioning to a new job a seamless and enjoyable process. Most benefits are effective on day one!

Axogen is an equal opportunity employer and does not discriminate against applicants on the basis of race, color, creed, religion, ancestry, age, sex, marital status, national origin, disability or veteran status.

Why you’ll love working at Axogen:

Friendly, open, and fun team culture that values unique perspectives
Company-wide dedication to profoundly impacting patients’ lives
Comprehensive, high-quality benefits package effective on date of hire
Educational assistance available for all employees
Matching 401(k) retirement plan
Paid holidays, including floating holidays, to be used at your discretion
Employee Stock Purchase Plan
Referral incentive program

Axogen Mission and Business Purpose

Our business purpose is to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care. We aim to lead the markets we serve by always requiring the solutions we offer patients and caregivers provide an improved benefit-to-risk profile as compared to existing standards of care. To ensure we deliver improved benefit-to-risk solutions, we will guide and expect the market and design requirement specifications underlying our engineering, business development, and clinical research activities, objectively target advancements in standards of care.

Job Summary of the Manager, Operational Technology & Manufacturing Systems

The Manager, Operational Technology & Manufacturing Systems serves as the senior technology leader for Axogen's Ohio manufacturing facility, providing leadership for onsite technology personnel and acting as the primary liaison between plant leadership and Corporate IT. Reporting to the Senior Director of IT, this role oversees and coordinates Operational Technology, infrastructure, cybersecurity, manufacturing applications, vendors, and enterprise IT resources to ensure reliable operations, regulatory compliance, project execution, and operational excellence. The Manager partners closely with Manufacturing, Quality, Engineering, Facilities, Laboratory, and Operations leaders to align technology priorities with business needs, coordinate activities with production schedules, remove barriers to execution, and minimize operational disruption. The role also leads technology planning team and vendor coordination for facility expansion, workforce growth, infrastructure modernization, and manufacturing system initiatives, ensuring technology capabilities support both current operations and long-term business objectives.

Requirements of the Manager, Operational Technology & Manufacturing Systems

Bachelor's degree in Information Systems, Computer Science, Engineering, Biotechnology, or a related discipline; or 8 years of related experience will be considered.
Minimum 7 years supporting enterprise, manufacturing, operational technology, computerized, or regulated systems.
Minimum 3 years of experience leading technical teams, managing vendor relationships, coordinating cross-functional resources, or directing technology projects in a manufacturing or regulated environment.
Experience with regulated production environments, system implementations, vendor management, facility technology, change control, validation support, and compliance documentation.
Strong communication, prioritization, relationship-management, and follow-through skills across plant leadership, operational teams, IT, contractors, and vendors.
Preferred knowledge of GxP, 21 CFR Part 11, validation, electronic records, manufacturing applications, low-voltage infrastructure, wireless networking, and OT cybersecurity.

Responsibilities of the Manager, Operational Technology & Manufacturing Systems

The specific duties of the Manager, Operational Technology & Manufacturing Systems include but are not limited to:

Serve as the senior onsite IT and Operational Technology (OT) leader and primary liaison between plant leadership, Corporate IT, and business stakeholders. Translate operational priorities, risks, strategic initiatives, and business needs into aligned technology roadmaps, support strategies, and execution plans.
Lead and develop the OT support team, establishing priorities, workload plans, escalation processes, support coverage, documentation standards, and service expectations while coordinating the efforts of Corporate IT personnel, application owners, vendors, contractors, and site resources regardless of reporting relationships.
Oversee operational support, maintenance, and lifecycle management of manufacturing technology systems. Maintain visibility to preventive maintenance, backups, incidents, changes, CAPAs, MOC activities, projects, and support activities, ensuring work is properly prioritized, documented, executed, and audit ready.
Direct technology planning and execution for site growth, infrastructure initiatives, and digital transformation efforts. Manage technology vendors and implementation partners while coordinating resources, schedules, dependencies, testing, installations, turnover activities, and technology investments that improve operational efficiency, data integrity, traceability, and business processes.
Partner with Production, Quality, Validation, Engineering, Facilities, and other stakeholders to govern technology changes, new system implementations, validation activities, CAPA resolution, and change control processes. Ensure alignment with enterprise architecture, cybersecurity requirements, IT policies, and regulatory expectations while supporting audit readiness and compliance.
Collaborate with Quality, Validation, and Corporate IT to maintain GxP, Part 11, data integrity, cybersecurity, disaster recovery, business continuity, and risk management programs across the OT environment.
Establish and maintain documentation, governance, and lifecycle standards, ensuring inventories, diagrams, procedures, runbooks, access records, maintenance histories, validation documentation, and technical records remain current, accurate, and audit ready.
Manage vendor performance, service levels, budgets, contracts, renewals, capital planning, forecasting, and technology investment priorities in partnership with the Senior Director of IT.

Location

913 Industrial Park Dr, Vandalia, OH 45377

#LI-AC1

Benefits/Compensation

This position is eligible for an annual bonus.

Benefits offered for this position include Health, Dental, Vision, Matching 401K, Paid Time Off, 9 Paid Holidays + 3 Floating Holidays, Dependent Care Flexible Spending Accounts, Medical Flexible Spending Accounts, Tuition Reimbursement, Paid Parental Leave, Paid Caregiver Leave, Basic Life Insurance, Supplemental Life Insurance, Employee Stock Purchase Plan, and Disability Insurance, as described in more detail in summary plan descriptions.

Salary Range

$113,903—$142,378 USD

Company Statements

Axogen follows healthcare system guidelines with respect to credentialing, vaccinations and other employment/compliance related requirements, as well as CDC guidance. Axogen reserves the right to amend its policies from time to time in its sole discretion.

As AI is becoming a common tool throughout the application process, we want to be clear about its appropriate use at Axogen. Using AI to support resume writing, research or interview preparation is perfectly acceptable, provided the content is accurate and genuinely represents your qualifications and skills. For other key parts of your interview process, however, it is important that the ideas, communication, and work you share reflect your own voice, experiences, and thinking. We ask that you participate in our live interviews and complete any assessments without AI assistance unless instructions explicitly indicate otherwise or a specific exception is discussed and approved in advance. This approach ensures fairness, celebrates your individuality, and allows your authentic perspective to shine. Behaviors that do not align with these guidelines may result in disqualification from the hiring process or termination of employment if later discovered. We appreciate your understanding and look forward to learning about the unique contributions only you can bring to Axogen.

No agency solicitation. We kindly request that recruiting agencies, staffing firms, and third‑party vendors do not contact us regarding this posting. Unsolicited résumés will not be considered.

Salary Range 113903 - 142378 USD

About the company

Axogen develops and sells surgical solutions specifically for repairing peripheral nerve damage. The company’s products, such as the Avance Nerve Graft, work by using processed human donor tissue to bridge gaps in severed nerves, while its Axoguard line provides protective wraps and connectors to shield nerves during the healing process. Unlike traditional methods that require a second surgery to harvest a patient's own healthy nerve, Axogen provides ready-to-use grafts that eliminate additional surgical trauma and potential lasting damage at a donor site. The company's goal is to provide surgeons with a comprehensive platform of clinically proven tools to restore nerve function and improve the quality of life for patients with nerve injuries.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Alachua, Florida

Founded

2002

Get referred to Axogen

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue rose 23.1% to $69.7 million; guidance lifted to $279 million.
Breast reconstruction drove over half of Q2 sales and expanded surgeon penetration.
September 2026 equity financing fully funds BioCircuit, preserving a cleaner balance sheet.

What critics are saying

Avance accelerated approvals depend on a confirmatory study through 2031; failure risks withdrawal.
September 2026 BioCircuit closing depends on note conversion, IP consent, and spin-out completion.
Q2 2026 gross margin fell to 72.7% while operating expenses reached $52.8 million.

What makes Axogen unique

Dec. 3, 2025 FDA BLA approval gives Avance durable regulatory credibility.
Axogen owns the only focused peripheral nerve repair platform spanning grafts, protectors, caps.
BioCircuit's NerveTape acquisition adds the first FDA-approved sutureless nerve repair device.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Holidays
Employee Stock Purchase Plan
Tuition Reimbursement
Paid Parental Leave
Paid Caregiver Leave
Basic Life Insurance
Supplemental Life Insurance

Growth & Insights and Company News

6 month growth

10%

1 year growth

12%

2 year growth

12%

Hoodline

Oct 5th, 2026

Axogen closes $200M BioCircuit deal, adding first sutureless nerve-repair device.

Axogen closes $200M BioCircuit deal, adding first sutureless nerve-repair device. Published on October 05, 2026 Axogen has finalized its $200 million acquisition of BioCircuit Technologies, a privately held medical device maker whose flagship product, NerveTape, is billed as the first FDA-cleared sutureless device for repairing severed peripheral nerves. The deal closed October 1, bringing a new surgical tool into the hands of a company that already bills itself as a global leader in restoring peripheral nerve function. Axogen first announced the agreement on September 10, saying it had entered into a definitive deal to acquire BioCircuit for $200 million in cash at closing, subject to customary adjustments, according to Axogen investor relations. At the time, the company said it expected the transaction to close in the fourth quarter, with the deal contingent on customary closing conditions, including completion of BioCircuit's electronics business spin-out. The agreement had already been approved by the boards of directors of both companies, per the same filing. The acquisition closed faster than the original fourth-quarter timeline suggested, with Axogen confirming completion on October 1, as reported by BioSpace. BioCircuit, based in Atlanta, Georgia, develops and commercializes medical devices for peripheral nerve repair and neuromodulation, the outlet noted. NerveTape, the company's signature device, is designed to simplify and enhance peripheral nerve repair procedures for surgeons treating transected nerves. What the deal means for Axogen's bottom line. Axogen expects BioCircuit to contribute roughly $6 million in fourth-quarter 2026 revenue and approximately $34 million in 2027 revenue, according to a report from Quiver Quant. That projected contribution was not part of the full-year 2026 guidance Axogen had most recently issued, which called for at least 24% revenue growth, the outlet noted. The company said it continues to expect gross margin of at least 73% and to remain free cash positive for the full year. Axogen had also said the deal is expected to be accretive to revenue growth, adjusted EBITDA margin, and adjusted earnings per share within the first year after closing, while the company maintains positive free cash flow, per Axogen investor relations. Taken together, the figures suggest Axogen is betting NerveTape can scale quickly inside its existing surgical sales channels rather than simply adding a one-off product line. Foley Hoag's role in closing the deal. The law firm Foley Hoag served as legal advisor to Axogen throughout the transaction, a role the firm detailed in its own account of the deal published Friday. Foley Hoag said its deal team was led by partner Mark Haddad of the firm's Boston office, with partners Earl Mellott, Allison Anderson, John Harre, Janine Ladislaw, and Barbara Klepper also involved, according to Foley Hoag. Associates Nitzan Fisher Conforti, Lee Ramati, Ariel Chen, Hannah Melville, and Alexandra Levay rounded out the team, the firm said, drawing on attorneys based in its Boston, New York, and Washington, D.C. offices. Axogen, which trades on the Nasdaq under the ticker AXGN, describes itself as a global leader in developing and marketing surgical solutions for the restoration of peripheral nerve function. With NerveTape now folded into its portfolio, the company has expanded its lineup of nerve repair technologies beyond the suture-based approaches that have long defined the field. A new option for nerve repair surgery. What makes NerveTape notable to surgeons is its sutureless approach. Rather than requiring stitches to rejoin a severed nerve, the device is positioned as a faster, simpler alternative, an incremental but meaningful shift for operating rooms handling peripheral nerve injuries. A U.S. Food and Drug Administration clearance document for the device describes it as indicated for repair of peripheral nerve discontinuities where gap closure can be achieved by flexion, though the publicly available excerpt of that filing cuts off before detailing the rest of the indication's full scope. For now, the deal's immediate impact is financial and strategic: Axogen gains a cleared device with projected near-term revenue, while BioCircuit's technology moves from a privately held startup into the hands of a Nasdaq-listed company with an established surgical sales network. Whether NerveTape reshapes nerve repair surgery as broadly as its first-of-its-kind FDA clearance suggests will likely play out over the next several fiscal quarters, as Axogen's own revenue projections for 2027 come into focus.

Foreign Policy Journal

Oct 4th, 2026

Nasdaq Composite surges on tech strength while (NYSE: RTX), (NASDAQ: IART), (NASDAQ: PECO) and (NASDAQ: AXGN) make market moves.

Nasdaq Composite surges on tech strength while (NYSE: RTX), (NASDAQ: IART), (NASDAQ: PECO) and (NASDAQ: AXGN) make market moves. Big technology drove the Nasdaq Composite to a weekly gain as the Dow Jones Industrial Average and Russell 2000 both closed the week in negative territory. The Nasdaq Composite jumped 1.18% on the day to close at 27,188.02, posting a weekly gain of 0.44% as chip and software names led the advance. The Dow Jones Industrial Average finished at 51,094.96, up 0.33% on the day but down 1.42% for the week, with an RSI14 of 38.1 signaling a weakening trend. The S&P 500 settled at 7,719.34, gaining 0.69% on Friday but slipping 0.31% for the week, while the Russell 2000 rose 0.97% on the day to 2,833.74 but edged down 0.13% for the week. The CBOE Volatility Index fell to 15.58, down 0.81 on the day, while WTI crude oil dropped 2.48% on the day and 2.19% for the week to settle at $90.57 a barrel. Gold eased 0.85% on the day to $4,166.60 an ounce, silver fell to $60.40, and the US 10-year Treasury yield rose 8 basis points for the week to 5.26%. RTX (NYSE: RTX) saw its Raytheon division secure a five-year contract with two additional option years valued at up to $24.4 billion for Standard Missile-6 interceptors for the U.S. Navy. Phil Jasper, Raytheon President, said: "SM-6's multi-mission capability is vital to our customer, and Raytheon is intensely focused on meeting the demand." Integra LifeSciences Holdings Corporation (NASDAQ: IART) provided preliminary third-quarter results, citing ongoing impact from a July flooding event at its Cincinnati facility, with expected revenue of approximately $410 million to $412 million. Stuart Essig, Chairman and Chief Executive Officer, said: "Our third quarter results were impacted by the July flooding event at our Cincinnati facility. Our teams have made significant progress executing recovery plans and supporting customers." IART lowered its full-year 2026 revenue outlook to $1.634 billion to $1.654 billion and cut adjusted EPS guidance to $2.30 to $2.40, while still targeting $190 million to $200 million in operating cash flow. Trilogy Metals Inc. (NYSE American: TMQ) reported a cash balance of $31.2 million as of August 31, 2026, and announced the closing of a $35.6 million strategic equity investment from the Department of War on September 11, 2026. Tony Giardini, President and CEO of Trilogy Metals, said: "The third quarter and the weeks that followed have been transformational for Trilogy Metals." Phillips Edison and Company, Inc. (NASDAQ: PECO) reaffirmed its full-year 2026 earnings guidance and raised its gross acquisitions target to $600 million to $700 million after acquiring $459.7 million in assets year to date through September 30, 2026. Jeff Edison, Chairman and Chief Executive Officer, said: "We're pleased to reaffirm our guidance for full year 2026 Core FFO per share growth, which reflects 6.2% year-over-year growth at the midpoint." Axogen, Inc. (NASDAQ: AXGN) completed its acquisition of BioCircuit Technologies, adding NerveTape, described as the first FDA cleared device for sutureless peripheral nerve repair. Michael Dale, President and Chief Executive Officer of Axogen, said: "NerveTape represents a new standard of care as the first sutureless nerve repair option, one that is simpler, faster, and more effective than microsuturing." Axogen expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to 2027 revenue, with the company maintaining its full-year 2026 guidance of at least 24% revenue growth.

BioPharma Watch

Oct 1st, 2026

Axogen completes acquisition of BioCircuit Technologies, adding NerveTape(TM), the first FDA cleared device for sutureless peripheral nerve repair.

Axogen completes acquisition of BioCircuit Technologies, adding NerveTape(TM), the first FDA cleared device for sutureless peripheral nerve repair. Key Takeaway: Axogen, Inc. has completed its acquisition of BioCircuit Technologies, known for its NerveTape(TM), the first FDA-cleared sutureless device for peripheral nerve repair. This acquisition is expected to significantly enhance Axogen's revenue, contributing approximately $6 million in Q4 2026 and $34 million in 2027. The integration of NerveTape(TM) aligns with Axogen's goal of improving standards in nerve repair. Market sentiment analysis. Positive Factors. * Acquisition enhances Axogen's product offerings with NerveTape(TM). * NerveTape(TM) is the first FDA-cleared sutureless device for nerve repair. * Expected revenue contributions from BioCircuit are significant. * Aligns with Axogen's mission to improve peripheral nerve repair. ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) - Axogen, Inc. ("Axogen" or the "Company") (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. ("BioCircuit"), a privately held medical device company and developer of NerveTape(TM). "This is a significant day for Axogen and the surgeons and patients we serve," said Michael Dale, President and Chief Executive Officer of Axogen. "NerveTape represents a new standard of care as the first sutureless nerve repair option - one that is simpler, faster, and more effective than microsuturing. This innovative technology directly addresses surgeons' everyday need to repair nerves and aligns perfectly with Axogen's mission to make the restoration of peripheral nerve function an expected standard of care. It is therefore an ideal fit with our direct sales organization and hospital contracting capabilities, enabling and unlocking NerveTape's full potential." The Company expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 and approximately $34 million to 2027 revenue. This contribution was not included in Axogen's most recently issued full-year 2026 guidance of at least 24% revenue growth. The Company continues to expect gross margin to be at least 73% and to be free cash positive for the full-year 2026. About Axogen. Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen's product portfolio includes Avance(R)(acellular nerve allograft-arwx), Avance(R) Nerve Graft, Axoguard Nerve Connector(R), Axoguard Nerve Protector(R), Axoguard HA+ Nerve Protector(TM), Axoguard Nerve Cap(R), and Avive+ Soft Tissue Matrix(R). About BioCircuit Technologies. BioCircuit Technologies, based in Atlanta, Georgia, develops and commercializes medical devices for peripheral nerve repair and neuromodulation, with expertise in biomaterials, precision Nitinol design and manufacturing, and bioelectronics for nerve stimulation and recording. Its first commercial product, NerveTape(TM), is the first FDA-cleared sutureless device for repairing transected nerves. BioCircuit has been supported by small business funding from the National Institutes of Health along with private investment from Alsora Capital, GRA Venture Fund, Michael Masters of Masters Capital Management, and other investors. For more information, visit www.biocircuit.com. Cautionary statements concernin g forward-looking statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding Axogen's ability to successfully integrate BioCircuit and realize the anticipated benefits of the acquisition, the expected financial impact of the acquisition and related financial guidance and outlook, including expected revenue, revenue growth, revenue contribution from BioCircuit in the fourth quarter of 2026 and in 2027, gross margin, free cash flow, as well as expectations regarding the commercialization and adoption of NerveTape and the expansion of Axogen's addressable market. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential," "upcoming" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties related to the integration of BioCircuit and the realization of the anticipated benefits of the acquisition and the risks and uncertainties inherent in Axogen's business, including the risks and uncertainties described in the Company's periodic filings with the SEC. The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Axogen can be found under the heading "Risk Factors" in Axogen's periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2025 and in its subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Axogen undertakes no obligation to update or revise any forward-looking statements contained herein. Frequently asked questions. What is NerveTape(TM)? NerveTape(TM) is the first FDA-cleared sutureless device for repairing transected nerves. How much revenue is expected from BioCircuit in 2027? BioCircuit is expected to contribute approximately $34 million to Axogen's revenue in 2027. What does the acquisition mean for Axogen's future? The acquisition enhances Axogen's product offerings and aligns with its mission to improve nerve repair standards. What are the benefits of NerveTape(TM)? NerveTape(TM) offers a simpler, faster, and more effective option for nerve repair compared to traditional microsuturing.

Axogen, Inc.

Sep 21st, 2026

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen’s addressable market within…...

StockTitan

Sep 10th, 2026

Axogen, Inc. 424B filings.

Axogen, Inc. 424B filings. AXGN NASDAQ Every 424B that Axogen, Inc. (AXGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it. A 424B covers the supplement that carries the terms of a priced offering, so if you follow AXGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AXGN filings page. 09/10/2026 04:56 PM Rhea-AI Summary Axogen, Inc. (AXGN) is conducting a primary offering of 4,910,000 shares of common stock at a public offering price of $42.50 per share, for gross proceeds of $208.7 million and estimated net proceeds of about $195.5 million after fees and expenses. Underwriters have a 30-day option to buy up to 736,500 additional shares. Shares outstanding will increase from 53,656,293 as of June 30, 2026 to 58,566,293 (or 59,302,793 if the option is fully exercised). The company plans to use substantially all net proceeds to fund the $200.0 million cash purchase of BioCircuit Technologies, Inc. and related costs, with any remainder for general corporate purposes; if the acquisition is not completed, all proceeds will be used for general corporate purposes. New investors face immediate dilution, as net tangible book value rises from $4.63 to $7.58 per share versus the $42.50 offering price. 01/23/2026 07:00 AM Rhea-AI Summary Axogen, Inc. is conducting a public offering of 4,000,000 shares of common stock at $31.00 per share, with underwriters holding a 30-day option to buy up to 600,000 additional shares. The company expects net proceeds of about $115.9 million (or $133.3 million if the option is fully exercised) and plans to use roughly $69.7 million to repay and terminate its Oberland credit facility, with the balance for working capital and capital spending. Axogen reports preliminary 2025 revenue of about $225.2 million, up roughly 20.2% year over year, and fourth-quarter revenue of about $59.9 million, up about 21.3%. Gross margin for 2025 and the fourth quarter is expected to be above 74%, including approximately $1.9 million in largely non-cash one-time costs tied to FDA approval milestones. On December 3, 2025, the FDA approved Axogen's Biologics License Application for Avance, an acellular nerve scaffold for specific sensory, mixed, and motor nerve indications, with certain uses granted under the accelerated approval pathway and subject to a confirmatory post-marketing study. 01/21/2026 04:59 PM Rhea-AI Summary Axogen is offering $85 million of common stock in a primary equity raise. The company has also granted underwriters a 30-day option to buy up to an additional $12.75 million of shares. Axogen currently intends to use a significant portion of the net proceeds to make an early payoff of its Oberland credit facility, with a final repayment amount expected to be approximately $69.7 million, which would terminate all obligations under that debt. Alongside the financing, Axogen outlines strong preliminary 2025 results, with expected revenue of about $59.9 million for the fourth quarter and $225.2 million for the full year, increases of 21.3% and 20.2% versus 2024. Gross margin for 2025 is expected to be above 74%, despite about $1.9 million of one-time costs tied to FDA approval of its Avance biologic. The company ended 2025 with approximately $45.5 million in cash, cash equivalents, restricted cash and investments, up about $6.0 million from a year earlier. The FDA approved Axogen's Biologics License Application for Avance in December 2025, granting full approval for certain sensory nerve indications and accelerated approval for longer sensory and mixed and motor nerve repairs, subject to a confirmatory post-marketing study running through 2030 with a final report due in 2031.

Axogen

Manager IT Operations - Biologics

About the job